There appears to be a financial hangover dogging large health care enterprises as government COVID subsidies expire. Novo Nordisk's monopoly pricing on insulin may be slipping, as well:
https://seekingalpha.com/news/4449520-novo-nordisk-stock-slips-ceo-steps-down
Novo Nordisk CEO to step down amid market challenges
By Dulan Lokuwithana - May 16, 2025Weight loss drugmaker Novo Nordisk (NVO) on Friday announced that its CEO, Lars Fruergaard Jørgensen, will resign from his leadership role as the company searches for his successor.
NVO said that the leadership transition was made in light of the company’s recent market challenges and the performance of its stock since mid-2024. Jørgensen has agreed to serve as the company’s CEO on an interim basis until his replacement is found.
The Danish pharma giant added that Lars Rebien Sørensen, chair of the Novo Nordisk Foundation, will join its board, initially as an observer. Novo Nordisk Foundation controls the company through its investment arm, Novo Holdings A/S.
Jørgensen, who joined Novo (NVO) in 1991, became the company’s CEO in January 2017, and during his eight-year tenure, NVO’s sales, profits, and share price have almost tripled.
“Serving as Novo Nordisk’s CEO for the past eight years has been a privilege and an experience that I will always cherish,” Jørgensen said.
Lars Rebien Sørensen has been serving as chair of the Novo Nordisk Foundation and Novo Holdings A/S since 2018 after a 16-year period as Novo Nordisk’s (NVO) CEO from 2000 to 2016.
Sponsors
Friends of MHF
Kirsten DeVries
Tom & Karen Nunheimer
Steve Ahonen
Ron & Faith Bosserman
Marlin & Kathy Klumpp
Sign Up for MHF Insights to keep up on the latest in Michigan Health Policy
